Cross-over Study on the Influence of Fampridine on Working Memory in Mild to Moderate Depression

Exclusion Criteria

• •Contraindications to the class of drugs under study, e.g. known hypersensitivity or allergy to 4-aminopyridine
• •Use of potassium channel blockers within the last 3 months
• •Treatment with OCT 2 inhibitors and -substrates (e.g. cimetidine, propranolol)
• •Treatment with antidepressants or antipsychotics within the last 3 months and throughout the study period
• •Current intake of psychoactive drugs (e.g. benzodiazepines, antidepressants, neuroleptics).
• •Other acute or chronic psychiatric disorder (e.g. psychosis, somatoform disorder, alcohol or drug abuse disorder)
• •Cognitive impairment (MoCA score \< 25)
• •MADRS item 10 \> 1 (suicidal tendency)
• •Risk of lowered seizure threshold (due to e.g. sleep deprivation, withdrawal of alcohol after alcohol abuse, hyponatraemia)
• •History of seizures
• •Acute cerebrovascular condition
• •Acute renal failure or severe renal insufficiency (creatinine clearance \< 30 ml/min per 1.73 m2)
• •Bradycardia \< 50/min during clinical examination.
• •History of malignant cancers
• •Walking problems (e.g. due to dizziness)
• •Other clinically significant concomitant disease states (e.g. hepatic dysfunction, cardiovascular disease, diabetes, asthma)
• •Clinically significant laboratory or ECG abnormality that could be a safety issue in the study
• •Severe somatic or neurological comorbidities
• •Smoking including all nicotine containing smoking systems and devices (\>10 cigarettes/units per day). Failure to withstand a test day without craving, due to regular consummation patterns.
• •Pregnancy or breast feeding. Intention to become pregnant during the study participation.
• •Known or suspected non-compliance
• •Inability to follow the procedures of the study, e.g. due to language or psychological problems of the participant
• •Participation in another study with an investigational drug within the 30 days preceding and during the present study
• •Enrolment of the investigator, his/her family members, employees and other dependent persons